Types A and B Niemann-Pick disease (NPD) result from inherited deficiencies of the lysosomal hydrolase, acid sphingomyelinase (ASM; sphingomyelin cholinephosphohydrolase, EC 3.1.4.X2). To evaluate the feasibility of somatic gene therapy for the treatment of these disorders, retroviralmediated gene transfer was used to introduce the full-length ASM cDNA into cultured fibroblasts from two unrelated type A NPD patients. The ASM activities in these cells were <4% of mean normal levels, and, consequently, they accumulated 3-fold elevated levels of sphingomyelin. After retroviralmediated transfer of the ASM cDNA, ASM activities in the NPD cells increased to levels up to 16-fold those found in normal fibroblasts. In addition, the sphingomyelin content was reduced to normal levels, indicating that the vector-encoded enzyme was properly targeted to lysosomes, where it was enzymatically active and able to degrade the accumulated substrate. In situ cell-loading studies also were undertaken to evaluate the effects of retroviral-mediated gene transfer on the pathology of NPD fibroblasts. When a pyrene derivative of sphingomyelin was introduced into the lysosomes of cultured fibroblasts from a type A NPD patient by using apolipoprotein E-mediated endocytosis, only -6% of the delivered substrate was degraded. In contrast, normal cells and NPD cells transduced (i.e., "corrected") by retroviral-mediated gene transfer could degrade -80% of the delivered sphingomyelin. These results provided further evidence that retroviral-mediated gene transfer may be used to correct the pathology of NPD cells. Cell-loading studies were also used to develop a selection system for discriminating between NPD cells and those transduced by retroviral-mediated gene transfer. This selection scheme was based on the fluorescence emission of intact NPD cells, which, when loaded with pyrene-labeled sphingomyelin, was 3-to 5-fold that of normal or transduced cells. As a consequence, the NPD and transduced cells could be efficiently sorted by flow cytometry with a fluorescence-activated cell sorter. In addition, the NPD cells could be selectively killed by photosensitization after irradiation with a long-wavelength UV light. These results should permit direct selection of ASM-expressing cells after retroviral-mediated gene transfer without the need to preselect for a cotransferred marker gene.
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Acid sphingomyelinase (ASM; sphingomyelin cholinephosphohydrolase, EC 3.1.4.12) is the lysosomal enzyme that hydrolyzes the neutral phospholipid sphingomyelin to ceramide and phosphocholine (1, 2) . In humans, the inherited deficiency of this enzymatic activity results in the neuronopathic (type A) and nonneuronopathic (type B) variants of Niemann-Pick disease (NPD) (3) . Patients with both forms of this disease have markedly deficient ASM activities and accumulate sphingomyelin and metabolically related lipids [e.g., cholesterol, bis(monoacylglycero)phosphate] within the lysosomes of most cell types. Accumulation of these lipids, particularly within cells of the reticuloendothelial system, leads to their respective clinical features. Type A NPD is characterized by early onset in infancy, failure to thrive, hepatosplenomegaly, cherry red maculae, and progressive neurodegeneration leading to severe psychomotor retardation and death by 3 yr of age. In contrast, type B NPD patients have hepatosplenomegaly, recurrent pulmonary infections, and little or no neurologic manifestations. Although the clinical course of type B NPD patients is variable, affected individuals often survive into the third decade of life.
Reports on the levels of residual ASM activity in NPD patients have varied due to differences in assay procedures and enzyme sources (4). In general, both type A and B NPD patients have in vitro residual enzymatic activities less than or equal to 10%o of that found in the same sources from normal individuals. Whether type B NPD patients have higher levels of residual ASM activity than type A patients has been the subject of much debate. Although sufficient data are not available to clearly resolve this issue, investigators have proposed this concept to provide a biochemical explanation for their distinct phenotypes. Recently, the full-length cDNA and genomic sequences encoding human ASM were isolated and characterized (5) (6) (7) (8) . These studies have facilitated identification of mutations that cause types A and B NPD (9, 10) (17) is a double-copy vector in which the BamHI-Bgl II fragment of the herpes simplex virus thymidine kinase gene promoter was inserted into the Bgl II site of the N2A vector, a modified N2 vector containing a polylinker region. To construct the ASM retroviral vectors (see Fig. 1 ), a 2.4-kilobase (kb) Sma I-Sma I fragment or a 2.2-kb Sma I-Nco I fragment was isolated from the full-length human ASM cDNA, pASM-3 (6), and inserted in the sense and antisense orientations by blunt-end ligation with T4 DNA ligase (18) . Before ligation of the Sma I-Nco I fragment into the retroviral vectors, the 5' overhang was filled in by using the Klenow fragment of DNA polymerase I. Unique Xho I and SnaBI restriction sites in the pBC140 and DCTK vectors, respectively, were used for the ligations to position the ASM cDNA sequences downstream from the heterologous promoter sequences. The recombinant vectors were used to transform competent JM109 cells for large-scale DNA isolation, and restriction enzyme analyses were used to identify vectors containing the ASM cDNAs in the sense or antisense orientations.
Generation of ASM-Contalning Retroviruses. Recombinant vector DNAs were transfected into the GP+envAM12 amphotropic packaging cell line (19) by electroporation. Transfected cells that contained integrated retroviral DNAs were isolated by using G418 selection (20) . For each vector, 12 colonies were isolated by ring cloning, expanded to cell lines, and analyzed for virus production. Supernatants from the producer cell lines containing high titers of recombinant virus (>104 colony-forming units/ml) were collected and stored at -800C until use. The absence of helper virus was demonstrated as described (19) .
Infection of NPD Cell Lines with Retroviral Vectors. Fibroblasts were infected at 25% confluency with vector viruses in Polybrene (8 Ag/ml). After 2 hr at 370C, viruses were removed, and fresh medium was added. G418 selection was begun on the following day at a final concentration of 0.5 mg/ml. For each infection, >100 G418-resistant colonies were pooled for further analyses.
Enzyme and Protein Determinations. The in vitro ASM activities were determined as previously described by using (22) . Protein concentrations were measured by a modified fluorescamine assay (23) . The in situ ASM activities were measured by using P10-Spm (24) with the following modifications. P10-Spm (10-25 nmol) was suspended in saline and subjected to ultrasonic irradiation (40%o output) with a microsonicator (Heat Systems/Ultrasonics) to generate small, unilamellar vesicles. These liposomes were mixed with apolipoprotein E (ApoE) (1 to =1.5 u.g/nmol of P10-Spm), and the mixtures were then added to the medium of confluent fibroblast cultures. After incubation for 12 hr, the cells were harvested by trypsinization, and the lipids were extracted in chloroform/methanol, 1:1 (vol/vol), at 600C for 10 min. The solvent was evaporated, and the individual lipids were resolved by sequential one-dimensional thin-layer chromatography in chloroform/methanol/H20, 90:10: 1, followed by chromatography in the same direction in chloroform/methanol/H20, 75:24:5. The pyrene ceramide and pyrene sphingomyelin bands were visualized with a UV lamp (366 nm), individually scraped from the thin-layer plates, resuspended in chloroform/methanol, 1:1 (vol/vol), and heated for 10 min at 60°C. The fluorescent intensities of the extracted lipids were determined at 343 (excitation) and 378 (emission) nm.
Sphingomyelin Determinations. Retrovirally transduced and untransduced fibroblasts were maintained in culture for at least 2 mo before harvesting by trypsinization. To determine sphingomyelin content, -1.0-5.0 x 106 cells were resuspended in a buffered solution (135 mM NaCl/4.5 mM KC1/1.5 mM CaC12/0.5 mM MgC12/5.6 mM glucose/10 mM Hepes, pH 7.4), and the phospholipids were extracted in chloroform/ methanol/concentrated HCI, 100:100:1 (vol/vol/vol), containing 10 mM EDTA (25) . Glycerophospholipids were then saponified in 0.4 M KOH/90%o methanol for 2 hr at 45°C, and the remaining, unhydrolyzed sphingomyelin was measured by a method based on complex formation between ammonium ferrothiocyanate and phospholipids (26) .
Fluorescence-Activated Cell Sorting (FACS). Flow cytometric analyses were performed as described (27) by using the FACS-440 sorting system (Becton Dickinson FACS Systems). Cells were excited at 351 nm, and an LP-420 filter was used to exclude scatter from the fluorescence detector. The photomultiplier tube voltage was set at 400 V, and logarithmic amplification was used. Cells were passed through the detector at a rate of =1000 cells per sec by using a 30-j&m ceramic nozzle and phosphate-buffered saline as the sheath fluid. The fibroblasts used were preincubated for 24 hr with P12-Spm/ApoE liposomes, harvested by trypsinization, and resuspended in saline.
Selective Photosensitization of NPD Cells. For selection of NPD cells by photosensitization, cells were loaded with P12-Spm for 24 hr with the ApoE-liposome delivery system described above. After harvesting by trypsinization, cells were resuspended in saline and irradiated for various times by using two 15-W lamps (Vilber-Lourmat, Marne-le Valees, France), which emitted long-wavelength UV bands from 320 to 380 nm (peak at 366 nm) at an incident radiation intensity of 7 mW/cm2. Cells that were damaged by the singlet oxygen released from the photoactivated pyrene (28) did not re-adhere and could be detected qualitatively in an inverted microscope. To determine the number of remaining cells the dishes were incubated for 2-4 days after irradiation, the remaining cells were harvested, and the protein content was determined as described above.
RESULTS
Construction of ASM Retroviral Vectors and in Vitro Expression. The two ASM-containing retroviral constructs used for transduction of NPD cells are diagrammed in Fig. 1 . ASM cDNAs of two different lengths were inserted into each vector. The Sma I-Sma I cDNA fragment, which contained the complete ASM-coding sequence, including 77 and 370 bp of 5' and 3' untranslated sequences, respectively, was inserted in the sense and antisense orientations into unique Xho I (pBC140) or SnaBI (DCTK) sites (constructs pBC-1 and DCTK-1, respectively). Alternatively, the Sma I-Nco I fragment, which included 77 and 242 bp of 5' and 3' untranslated sequences, respectively, was inserted in the sense and antisense orientations (constructs pBC-2 and DCTK-2). The retroviral vector constructs were packaged into infectious viral particles with the GP+envAM12 amphotropic packaging cell line (viral titers >104 colony forming units/ml) and used to infect cultured fibroblasts from two unrelated type A NPD patients. Table 1 shows the ASM activities in these cells toward the fluorescent natural substrate PSA11-Spm. Cultured fibroblasts obtained from proband 1 contained <1% of the mean activities in normal cells. In comparison, infection with the sense-oriented retroviral vectors resulted in ASM activities that were increased up to 1221 nmol per hr/mg of protein, or l16-fold greater than normal (i.e., '3000-fold over the average NPD ASM activity). No significant differences in enzymatic activity were found between the two cDNAs containing ASMs of different lengths (i.e., the Sma I-Sma I and Sma I-Nco I fragments); however, the pBC140 vector consistently expressed considerably higher levels of ASM activities than the DCTK vector. Notably, a significant variation in ASM expression was seen when independent infections were done with the same retroviral construct. For example, when the pBC-1 vector was used for six independent infections, ASM specific activities varied from 342 to 1221 nmol per hr/mg. Similar results were obtained with cultured fibroblasts from proband 2, an unrelated type A NPD patient ( fibroblasts in ApoE-coated liposomes. After incubation of the cells with ApoE/P1O-Spm liposomes, in situ ASM activities were determined by harvesting the cells and measuring the percent of fluorescent sphingomyelin converted to ceramide (see Materials and Methods). Table 2 shows that after a 12-hr incubation normal cultured fibroblasts degraded 80%o of the P10-Spm, whereas the type A NPD cells from proband 1 infected with antisense retroviral constructs degraded only -7% of the substrate. Notably, the NPD cells infected with the ASM sense constructs degraded up to 83% of the endocytosed substrate, similar to levels obtained with normal cells. These results provided further evidence that the retrovirally expressed ASM was properly targeted to lysosomes and catalytically active in situ.
Sphingomyelin Determinations. Fig. 2 shows that cultured fibroblasts obtained from type A NPD probands 1 and 2 accumulated sphingomyelin at levels up to 3-fold over those found in normal fibroblasts. After infection of each NPD cell line with the sense-orientated ASM vectors and expression of the vector-encoded enzyme for up to 2 mo in culture, the sphingomyelin levels were reduced to and maintained at essentially normal levels.
Flow Cytometric Sorting and Selective Photosensitization of NPD Cells. Suspensions of type A NPD fibroblasts incubated for 24 hr with P12-Spm had three to five times higher fluores- (antisense) 7.5 ± 2.8 The in situ enzyme assays were done as described by using P10-Spm and the ApoE-liposome delivery system. *Values represent the mean of three or more determinations.
cence emission intensities than similarly treated normal fibroblasts (data not shown). Based on these findings, flow cytometric analyses in the FACS was performed with normal fibroblasts and type A NPD fibroblasts expressing vectorencoded ASM (Fig. 3) . Note that the distribution and peak fluorescence of the uninfected (Fig. 3B) and transduced (Fig.  3C ) NPD fibroblasts were distinctly different; there was almost no region of overlap. Thus, these results showed the feasibility of directly isolating transduced NPD cells without preselecting for a cotransferred selectable marker gene, such as neo.
These results also suggested that untreated and transduced NPD cells (or normal cells) could be selected by their differential photosensitization properties after loading with pyrene-labeled sphingomyelin. Fig. 4 shows that irradiation of pyrene-loaded type A NPD fibroblasts for 15-20 min by using a long-wavelength UV source effectively killed all of the cells. Similar results were obtained with NPD cells containing antisense retroviral constructs that did not express catalytically active ASM. In contrast, =60% of normal fibroblasts and NPD fibroblasts expressing the vectorencoded ASM could survive this irradiation period. These results indicated that after retroviral-mediated transduction of NPD cells, those cells expressing sufficient levels of ASM activity to degrade the pyrene-labeled substrate could be efficiently isolated from nonexpressing cells without any need for neo preselection. is targeted to the major cellular sites of pathology in sufficient amounts to correct the metabolic defect. For types A and B NPD, the transferred ASM gene must be expressed in reticuloendothelial cells and targeted to the lysosomes to degrade the accumulated substrate and maintain normal sphingomyelin levels. For type A NPD, ASM also must be expressed in neurons in the central nervous system.
The in vitro and in situ studies described here were undertaken to evaluate, at the cellular level, the feasibility of somatic gene therapy for type B NPD. Although both pBC140 and DCTK vectors expressed high levels of ASM activity, the "N2-type" pBC140 vector, which contained a cytomegalovirus promoter sequence, consistently expressed higher levels of enzymatic activity in the NPD fibroblasts. Whether this result was due to the promoter sequences themselves (the DCTK vector has a herpes simplex virus thymidine kinase gene promoter) or the differential expression and/or stability of the different vector RNAs in cultured fibroblasts, is not known. Also, the expression of an ASM cDNA with deleted 3' untranslated sequences was evaluated because absence of these sequences has been suggested to lead to increased RNA stability and, hence, higher levels of enzyme expression (31) . However, this modification did not alter ASM expression from either retroviral vector (Table 1) .
Importantly, the retroviral-mediated expression of ASM reduced the accumulated sphingomyelin in NPD fibroblasts to normal levels. These results suggested that the vector- Genetics: Suchi et al.
. a I I encoded ASM was targeted to the lysosomal compartments, where it could recognize and degrade its primary substrate sphingomyelin. To further evaluate catalytic activity of the vector-encoded enzyme, an in situ cell-loading assay was used (24) . In this assay fluorescently labeled sphingomyelin was delivered to lysosomes with ApoE-coated liposomes, and the levels of the fluorescent substrate were determined 12 hr later. Normal fibroblasts and NPD fibroblasts expressing the vector-encoded ASM could degrade -80% of delivered substrate, whereas uninfected NPD cells and cells infected with antisense retroviral constructs could only degrade -7% of exogenous substrate. The results of these in situ assays confirmed those obtained from the in vitro enzyme assays in which the cells were disrupted before determining activity of the expressed enzyme toward labeled sphingomyelin added to the assay mixture. Thus, the type A NPD cells were metabolically "corrected" by retroviral-mediated expression of human ASM. For type B NPD, somatic gene therapy will probably involve efforts to transfer the ASM gene into bone marrow stem cells because the primary site of pathology is the reticuloendothelial system. To date, a major obstacle to stem cell gene transfer has been the inability to efficiently target retroviral vectors to bone marrow stem cells and obtain sufficient numbers of transduced cells for transplantation. Currently, most retroviral-mediated gene transfer protocols use G418 selection to identify transduced cells expressing the cotransferred neo gene. However, these cells then must be analyzed to insure that they also express the gene of interest. In addition, this approach may not have broad applicability because it has recently been reported that the long-term expression of retrovirally transferred genes in mice was dramatically improved by the use of simplified retroviral vectors that lack the neo gene (32) .
Therefore, a series of experiments were undertaken to develop a direct selection procedure for the isolation of retrovirally infected NPD cells that express catalytically active ASM. We reasoned that because intact NPD cells, loaded with P12-Spm using the ApoE-mediated liposome delivery system, had a fluorescence-emission intensity three to five times greater than their normal counterparts, it should be possible to sort NPD cells from those expressing vectorencoded ASM; i.e., "corrected" NPD cells could be selected by flow cytometry and photosensitization. Why the NPD cells have a greater fluorescence-emission is not clear; however, this effect was due to either the fact that in NPD cells the P12-Spm was localized to a more hydrophobic environment than in normal cells, permitting longer half-life of the excited pyrene forms, or that, alternatively, in normal cells the P12-Spm was degraded to P12-ceramide, which was more rapidly secreted out of the cells. Fig. 3 shows that NPD cells expressing human ASM had a different fluorescence distribution than nontransduced cells, permitting flow cytometric sorting in a FACS and isolation of the selected cells for further studies. In addition, NPD cells could be selectively killed by exposure to long-wavelength UV light, permitting isolation of only those transduced cells expressing enough ASM to degrade the fluorescent substrate. These results provide the basis for future studies to directly select NPD bone marrow stem cells that are expressing vector-encoded ASM without the need for preselection with antibiotics or other nonphysiologic compounds for a cotransferred marker gene.
In summary, our results show that retroviral-mediated gene transfer may be used to correct the metabolic defect in type A NPD cells. The vector-encoded ASM was properly targeted to lysosomes, where it could recognize and degrade both the endogenous, accumulated sphingomyelin, as well as fluorescently labeled substrate that was administered into the cells by receptor-mediated endocytosis. In addition, as an alternative to the use of G418 or other nonphysiologic compounds for selection in gene-transfer protocols, use of fluorescence sorting and selective photosensitization was evaluated to permit the isolation of transduced NPD cells for future therapeutic endeavors in animal models or humans with NPD. 
